Treatment response evaluation by MRI in breast cancer patients receiving neoadjuvant chemotherapy: There is more than just pathologic complete response prediction

Breast Cancer Research and Treatment

Volumn 136, Issue 1, 2012, Pages 313-314

  Lobbes, M B I ^a,b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; DOCETAXEL; TAXANE DERIVATIVE;

ADJUVANT THERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIFFUSION WEIGHTED IMAGING; HUMAN; LETTER; MASTECTOMY; MINIMAL RESIDUAL DISEASE; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TREATMENT INDICATION; TREATMENT RESPONSE;

DIFFUSION MAGNETIC RESONANCE IMAGING; HUMANS; LIVER NEOPLASMS;

EID: 84867874446     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2180-8     Document Type: Letter

References (12)

1. Wu L, Hu J, Gu H, Hua J, Chen J, Xu R (2012) Can diffusion-weighted MR imaging and contrast-enhanced MR imaging precisely evaluate and predict pathological response to neoadjuvant chemotherapy in patients with breast cancer? Breast Cancer Res Treat [Epub ahead of print, April 4]
2. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN (2007) Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 608:1-22
3. Partridge SC, Gibbs JE, Lu Y et al (2002) Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. AJR Am J Roentgenol 179:1193-1199
4. Cheung Y, Chen S, Su M et al (2003) Monitoring the size and response of locally advanced breast cancers to neoadjuvant chemotherapy (weekly paclitaxel and epirubicin) with serial enhanced MRI. Breast Cancer Res Treat 78:51-58
5. Nakahara H, Yasuda Y, Machida E et al (2011) MR and US imaging for breast cancer patients who underwent conservation surgery after neoadjuvant chemotherapy: comparison of triple negative breast cancer and other intrinsic subtypes. Breast Cancer 18:152-160
6. Yeh E, Slanetz P, Kopans DB et al (2005) Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. AJR Am J Roentgenol 184:868-877
7. Belli P, Costantini M, Malaspina C, Magistrelli A, LaTorre G, Bonomo L (2006) MRI accuracy in residual disease evaluation in breast cancer patients treated with neoadjuvant chemotherapy. Clin Radiol 61:946-953
8. Kim HJ, Im Y, Han B et al (2007) Accuracy of MRI for estimating residual tumor size after neoadjuvant chemotherapy in locally advanced breast cancer: relation to response patterns on MRI. Acta Oncol 46:996-1003
9. Segara D, Krop IE, Garber JE et al (2007) Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy? J Surg Oncol 96:474-480
10. Denis F, Desbiez-Bourcier AV, Chapiron C, Arbion F, Body G, Brunereau L (2004) Contrast enhanced magnetic resonance imaging underestimates residual disease following neoadjuvant docetaxel based chemotherapy for breast cancer. Eur J Surg Oncol 30:1069-1076
11. Loo CE, Straver ME, Rodenhuis S et al (2011) Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype. J Clin Oncol 29:660-666
12. Chen JH, Feig B, Agrawal G et al (2008) MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy. Cancer 112:17-26